Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0142 Transporter Info | ||||
| Gene Name | SLC22A16 | ||||
| Protein Name | Fly-like putative transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs12210538 | ||||
| Site of GPD | chr6:110438805 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Minor Allele Frequency | G=0.0915/458 (Global) | ||||
| Allele A | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Doxorubicin | Drug Info | Breast Neoplasm | Irrelevant to the likelihood of febrile neutropenia in patients (compare with Allele G) | [ 1] | |
| Allele G | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Doxorubicin | Drug Info | Breast Neoplasm | Correlated with the increased likelihood of drug toxicity in patients (compare with Allele A) | [ 2] | |
| Cyclophosphamide | Drug Info | Breast Neoplasm | Correlated with the increased likelihood of drug toxicity in patients (compare with Allele A) | [ 2] | |
| Genetic Polymorphism | rs6907567 | ||||
| Site of GPD | chr6:110456759 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Minor Allele Frequency | G=0.3141/1573 (Global) | ||||
| Allele G | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Doxorubicin | Drug Info | Breast Neoplasm | Correlated with the decreased likelihood of dose delay in patients (compare with Allele A) | [ 2] | |
| Cyclophosphamide | Drug Info | Breast Neoplasm | Correlated with the decreased likelihood of dose delay in patients (compare with Allele A) | [ 2] | |
| Genotypes AG + GG | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Fluorouracil | Drug Info | Breast Neoplasm | Correlated with the decreased neutropenia risk in patients (compare with Genotype AA) | [ 3] | |
| Doxorubicin | Drug Info | Breast Neoplasm | Correlated with the decreased neutropenia risk in patients (compare with Genotype AA) | [ 3] | |
| Cyclophosphamide | Drug Info | Breast Neoplasm | Correlated with the decreased neutropenia risk in patients (compare with Genotype AA) | [ 3] | |
| Genetic Polymorphism | rs714368 | ||||
| Site of GPD | chr6:110456925 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | T>C | ||||
| Minor Allele Frequency | C=0.3139/1572 (Global) | ||||
| Allele C | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Doxorubicin | Drug Info | Breast Neoplasm | Correlated with the decreased likelihood of dose delay in patients (compare with Allele T) | [ 2] | |
| Cyclophosphamide | Drug Info | Breast Neoplasm | Correlated with the decreased likelihood of dose delay in patients (compare with Allele T) | [ 2] | |
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Doxorubicin | Drug Info | Breast Neoplasm | Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in patients (compare with genotypes tt + Ct) | [ 4] | |
| Doxorubicinol | N.A. | Breast Neoplasm | Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in patients (compare with genotypes tt + Ct) | [ 4] | |
| Genotypes CC + CT | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Fluorouracil | Drug Info | Breast Neoplasm | Correlated with the increased nausea risk in patients (compare with Genotype TT) | [ 3] | |
| Doxorubicin | Drug Info | Breast Neoplasm | Correlated with the increased nausea risk in patients (compare with Genotype TT) | [ 3] | |
| Cyclophosphamide | Drug Info | Breast Neoplasm | Correlated with the increased nausea risk in patients (compare with Genotype TT) | [ 3] | |
| Genetic Polymorphism | rs723685 | ||||
| Site of GPD | chr6:110442672 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Minor Allele Frequency | G=0.0881/441 (Global) | ||||
| Allele G | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Doxorubicin | Drug Info | Breast Neoplasm | Correlated with the decreased likelihood of dose delay in patients (compare with Allele A) | [ 2] | |
| Cyclophosphamide | Drug Info | Breast Neoplasm | Correlated with the decreased likelihood of dose delay in patients (compare with Allele A) | [ 2] | |
| References | |||||
| 1 | Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. PLoS One. 2016 Dec 30;11(12):e0168519. | ||||
| 2 | Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9. | ||||
| 3 | Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136. | ||||
| 4 | Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007 Jun;8(6):567-75. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.